Arch Biopartners Inc
XTSX:ARCH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.12
2.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Arch Biopartners Inc
Arch Biopartners Inc
Total Receivables
Arch Biopartners Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Total Receivables
CA$1.5m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
74%
|
CAGR 10-Years
54%
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Total Receivables
$64.4m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Total Receivables
CA$103.8k
|
CAGR 3-Years
21%
|
CAGR 5-Years
48%
|
CAGR 10-Years
18%
|
|
|
Innovotech Inc
XTSX:IOT
|
Total Receivables
CA$204.8k
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
Arch Biopartners Inc
Glance View
Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.
See Also
What is Arch Biopartners Inc's Total Receivables?
Total Receivables
1.5m
CAD
Based on the financial report for Jun 30, 2024, Arch Biopartners Inc's Total Receivables amounts to 1.5m CAD.
What is Arch Biopartners Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
54%
Over the last year, the Total Receivables growth was 12 267%. The average annual Total Receivables growth rates for Arch Biopartners Inc have been -18% over the past three years , 74% over the past five years , and 54% over the past ten years .
You don't have any saved screeners yet
